Evidence map›Paper›PMID 32707884›Full record

ReviewCancers2020

Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma.

Konstantinos Papadimitriou, Ioannis V Kostopoulos, Anastasia Tsopanidou, Nikolaos Orologas-Stavrou, Efstathios Kastritis, Ourania Tsitsilonis, Meletios A Dimopoulos, Evangelos Terpos

Abstract readReview
In one paragraph

Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. A 3D-Bioprinted Multiple Myeloma Model.Advanced healthcare materials · 2022
    Article
  10. Generation of Induced Pluripotent Stem Cells from Patients with Multiple MyelomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021
    Article
  11. Observational
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Konstantinos PapadimitriouDepartment of Biology, School of Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.ORCID 0000-0002-8902-8522
Ioannis V KostopoulosDepartment of Biology, School of Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.ORCID 0000-0003-1152-6959
Anastasia TsopanidouDepartment of Biology, School of Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.
Nikolaos Orologas-StavrouDepartment of Biology, School of Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.
Efstathios KastritisDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Ourania TsitsilonisDepartment of Biology, School of Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece.ORCID 0000-0001-6954-0740
Meletios A DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Evangelos TerposDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-5133-1422

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) remains incurable despite the abundance of novel drugs. As it has been previously shown, preclinical 2D models fail to predict disease progression due to their inability to simulate the microenvironment of the bone marrow. In this review, we focus on 3D models and present all currently available ex vivo MM models that fulfil certain criteria, such as development of complex 3D environments using patients' cells and ability to test different drugs in order to assess personalized MM treatment efficacy of various regimens and combinations. We selected models representing the top-notch ex vivo platforms and evaluated them in terms of cost, time-span, and feasibility of the method. Finally, we propose where such a model can be more informative in a patient's treatment timeline. Overall, advanced 3D preclinical models are very promising as they may eventually offer the opportunity to precisely select the optimal personalized treatment for each MM patient.

Indexed as

3D modelbone marrow microenvironmentmultiple myelomapersonalized therapyprecision medicine

Identifiers

PMID32707884
PMCPMC7463609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.